Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Guardant Health's Enterprise Value is $4,162.9 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-397.9 Mil. Therefore, Guardant Health's EV-to-EBIT ratio for today is -10.46.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Guardant Health's Enterprise Value is $4,162.9 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-373.4 Mil. Therefore, Guardant Health's EV-to-EBITDA ratio for today is -11.15.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Guardant Health's Enterprise Value is $4,162.9 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $391.1 Mil. Therefore, Guardant Health's EV-to-Revenue ratio for today is 10.64.
Guardant Health Enterprise Value Historical Data
The historical data trend for Guardant Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Enterprise Value
-
2,849.28
6,932.78
12,032.29
10,619.72
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Enterprise Value
14,899.95
12,196.71
12,636.56
10,619.72
7,166.31
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Enterprise Value Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Guardant Health's Enterprise Value falls into.
Guardant Health Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Guardant Health's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Guardant Health's current Enterprise Value is $4,162.9 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-397.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Guardant Health's current Enterprise Value is $4,162.9 Mil.
Guardant Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-373.4 Mil.
Guardant Health's current Enterprise Value is $4,162.9 Mil.
Guardant Health's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $391.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health Enterprise Value Related Terms
Thank you for viewing the detailed overview of Guardant Health's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.21(3.29%) Volume: 1,806,277 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
